Background:
Although antiviral therapy is cost-effective in adults, its cost-effectiveness in older adults has not been studied.
Objective:
To determine the cost-effectiveness of influenza testing and treatment strategies for older adults.
Design:
Costutility decision model.
Data Sources:
Clinical trials of antiviral drugs and epidemiologic data.
Target Population:
Noninstitutionalized adults older than 65 years of age with influenza-like illness.
Time Horizon:
Lifetime.
Perspective:
Societal.
Interventions:
Rapid diagnostic testing or empirical therapy with antiviral drugs.
Outcome Measures:
Cost per quality-adjusted life-year (QALY) saved.
Results of Base-Case Analysis:
Compared with no intervention, empirically treating an unvaccinated 75-year-old patient with amantadine increased life expectancy by 0.0014 QALY at a cost of $1.57, a cost-effectiveness ratio of $1129 per QALY saved. Compared with amantadine, rapid diagnostic testing followed by treatment with oseltamivir cost $5025 per QALY saved and empirical treatment with oseltamivir cost $10 296 per QALY saved. Testing and treatment strategies were less cost-effective if the patient was vaccinated, ranging from $2483 per QALY saved with amantadine to $70 300 per QALY saved with oseltamivir.
Results of Sensitivity Analysis:
The decision was sensitive to the probability of influenza, the efficacy of oseltamivir in preventing hospitalizations, and hospitalization and case-fatality rates. The decision was not sensitive to the probability or severity of medication side effects, the quality of life for influenza illness or hospitalization, the efficacy of antiviral therapy in shortening influenza illness, or the rapid diagnostic test characteristics.
Conclusions:
For unvaccinated or high-risk vaccinated patients during the influenza season, empirical oseltamivir treatment is cost-effective. For other patients, rapid diagnostic testing followed by treatment with oseltamivir is cost-effective. Empirical amantadine treatment offers a low-cost alternative if patients cannot afford oseltamivir.
References
- 1.
Bridges CB ,Fukuda K ,Uyeki TM ,Cox NJ ,Singleton JA . Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2002;51:1-31. [PMID:12002171 ] MedlineGoogle Scholar - 2.
Simonsen L ,Fukuda K ,Schonberger LB ,Cox NJ . The impact of influenza epidemics on hospitalizations. J Infect Dis. 2000;181:831-7. [PMID:10720501 ] CrossrefMedlineGoogle Scholar - 3.
Jefferson T ,Demicheli V ,Rivetti D ,Deeks J . Cochrane reviews and systematic reviews of economic evaluations. Amantadine and rimantadine in the prevention and treatment of influenza. Pharmacoeconomics. 1999;16Suppl 1 85-9. [PMID:10623381 ] CrossrefMedlineGoogle Scholar - 4.
Wenzel RP . Expanding the treatment options for influenza [Editorial]. JAMA. 2000;283:1057-9. [PMID:10697068 ] CrossrefMedlineGoogle Scholar - 5.
Hayden FG ,Atmar RL ,Schilling M ,Johnson C ,Poretz D ,Paar D ,10536125 ] CrossrefMedlineGoogle Scholar - 6.
Hayden FG ,Osterhaus AD ,Treanor JJ ,Fleming DM ,Aoki FY ,Nicholson KG ,9302301 ] CrossrefMedlineGoogle Scholar - 7.
Treanor JJ ,Hayden FG ,Vrooman PS ,Barbarash R ,Bettis R ,Riff D ,10697061 ] CrossrefMedlineGoogle Scholar - 8.
Monto AS ,Fleming DM ,Henry D ,de Groot R ,Makela M ,Klein T ,10395837 ] CrossrefMedlineGoogle Scholar - 9.
Matsumoto K ,Ogawa N ,Nerome K ,Numazaki Y ,Kawakami Y ,Shirato K ,10682150 ] MedlineGoogle Scholar - 10. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Lancet. 1998;352:1877-81. [PMID:
9863784 ] CrossrefMedlineGoogle Scholar - 11.
Lalezari J ,Campion K ,Keene O ,Silagy C . Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized, controlled trials. Arch Intern Med. 2001;161:212-7. [PMID:11176734 ] CrossrefMedlineGoogle Scholar - 12.
Kaiser L ,Keene ON ,Hammond JM ,Elliott M ,Hayden FG . Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults. Arch Intern Med. 2000;160:3234-40. [PMID:11088083 ] CrossrefMedlineGoogle Scholar - 13.
Bowles SK ,Lee W ,Simor AE ,Vearncombe M ,Loeb M ,Tamblyn S ,11982659 ] CrossrefMedlineGoogle Scholar - 14. Two neuraminidase inhibitors for treatment of influenza. Med Lett Drugs Ther. 1999;41:91-3. [PMID:
10535051 ] MedlineGoogle Scholar - 15.
Lee PY ,Matchar DB ,Clements DA ,Huber J ,Hamilton JD ,Peterson ED . Economic analysis of influenza vaccination and antiviral treatment for healthy working adults. Ann Intern Med. 2002;137:225-31. [PMID:12186512 ] LinkGoogle Scholar - 16.
Zambon M ,Hays J ,Webster A ,Newman R ,Keene O . Diagnosis of influenza in the community: relationship of clinical diagnosis to confirmed virological, serologic, or molecular detection of influenza. Arch Intern Med. 2001;161:2116-22. [PMID:11570941 ] CrossrefMedlineGoogle Scholar - 17.
Govaert TM ,Dinant GJ ,Aretz K ,Knottnerus JA . The predictive value of influenza symptomatology in elderly people. Fam Pract. 1998;15:16-22. [PMID:9527293 ] CrossrefMedlineGoogle Scholar - 18.
Boivin G ,Hardy I ,Tellier G ,Maziade J . Predicting influenza infections during epidemics with use of a clinical case definition. Clin Infect Dis. 2000;31:1166-9. [PMID:11073747 ] CrossrefMedlineGoogle Scholar - 19.
Monto AS ,Webster A ,Keene O . Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. J Antimicrob Chemother. 1999;44Suppl B 23-9. [PMID:10877459 ] CrossrefMedlineGoogle Scholar - 20.
Nicholson KG ,Aoki FY ,Osterhaus AD ,Trottier S ,Carewicz O ,Mercier CH ,10866439 ] CrossrefMedlineGoogle Scholar - 21.
Nicholson KG ,Kent J ,Hammersley V ,Cancio E . Acute viral infections of upper respiratory tract in elderly people living in the community: comparative, prospective, population based study of disease burden. BMJ. 1997;315:1060-4. [PMID:9366736 ] CrossrefMedlineGoogle Scholar - 22. Centers for Disease Control and Prevention. Reports & Surveillance Methods in the United States: Current U.S. Flu Report, 2002. Accessed at www.cdc.gov/ncidod/diseases/flu/weeklychoice.htm on 26 March 2002. Google Scholar
- 23.
Barker WH ,Mullooly JP . Impact of epidemic type A influenza in a defined adult population. Am J Epidemiol. 1980;112:798-811. [PMID:7457471 ] CrossrefMedlineGoogle Scholar - 24.
Nichol KL ,Wuorenma J ,von Sternberg T . Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med. 1998;158:1769-76. [PMID:9738606 ] CrossrefMedlineGoogle Scholar - 25.
Cox FM ,Cobb MM ,Chua WQ ,McLaughlin TP ,Okamoto LJ . Cost of treating influenza in emergency department and hospital settings. Am J Manag Care. 2000;6:205-14. [PMID:10977420 ] MedlineGoogle Scholar - 26.
Libow LS ,Neufeld RR ,Olson E ,Breuer B ,Starer P . Sequential outbreak of influenza A and B in a nursing home: efficacy of vaccine and amantadine. J Am Geriatr Soc. 1996;44:1153-7. [PMID:8855992 ] CrossrefMedlineGoogle Scholar - 27.
Keyser LA ,Karl M ,Nafziger AN ,Bertino JS . Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients. Arch Intern Med. 2000;160:1485-8. [PMID:10826462 ] CrossrefMedlineGoogle Scholar - 28.
Hayden FG ,Treanor JJ ,Fritz RS ,Lobo M ,Betts RF ,Miller M ,10517426 ] CrossrefMedlineGoogle Scholar - 29.
Hayden FG ,Treanor JJ ,Betts RF ,Lobo M ,Esinhart JD ,Hussey EK . Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA. 1996;275:295-9. [PMID:8544269 ] CrossrefMedlineGoogle Scholar - 30.
Diggory P ,Fernandez C ,Humphrey A ,Jones V ,Murphy M . Comparison of elderly people's technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial. BMJ. 2001;322:577-9. [PMID:11238150 ] CrossrefMedlineGoogle Scholar - 31.
Govaert TM ,Thijs CT ,Masurel N ,Sprenger MJ ,Dinant GJ ,Knottnerus JA . The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA. 1994;272:1661-5. [PMID:7966893 ] CrossrefMedlineGoogle Scholar - 32. Demicheli V, Rivetti D, Deeks JJ, Jefferson TO. Vaccines for preventing influenza in healthy adults [Review]. Cochrane Database Syst Rev. 2001:CD001269. [PMID: 11687102] Google Scholar
- 33.
Griffin AD ,Perry AS ,Fleming DM . Cost-effectiveness analysis of inhaled zanamivir in the treatment of influenza A and B in high-risk patients. Pharmacoeconomics. 2001;19:293-301. [PMID:11303417 ] CrossrefMedlineGoogle Scholar - 34. 2001 Drug Topics Red Book. Montvale, NJ: Medical Economics; 2001. Google Scholar
- 35. Crane M. What you charge vs what you get. Med Econ. 2001; 78:50-2, 55-7. [PMID: 11715372] Google Scholar
- 36. Rapid diagnostic tests for influenza. Med Lett Drugs Ther. 1999;41:121-2. [PMID:
10987012 ] MedlineGoogle Scholar - 37.
Dolin R ,Reichman RC ,Madore HP ,Maynard R ,Linton PN ,Webber-Jones J . A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med. 1982;307:580-4. [PMID:7050702 ] CrossrefMedlineGoogle Scholar - 38. Relenza (zanamivir for inhalation) [Package insert]. Research Triangle Park, NC: Glaxo Wellcome; 2001. Google Scholar
- 39.
Gold M ,Siegel J ,Russell L ,Weinstein M ,eds . Cost-Effectiveness in Health and Medicine. New York: Oxford Univ Pr; 1996. Google Scholar - 40. U.S. Department of Labor, Bureau of Labor Statistics. Consumer Price IndexAll Urban Consumers. Accessed at www.bls.gov/data/ on 6 May 2002. Google Scholar
- 41. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA. 2002;287:2542-51. [PMID:
12020335 ] CrossrefMedlineGoogle Scholar - 42.
Kerlikowske K ,Salzmann P ,Phillips KA ,Cauley JA ,Cummings SR . Continuing screening mammography in women aged 70 to 79 years: impact on life expectancy and cost-effectiveness. JAMA. 1999;282:2156-63. [PMID:10591338 ] CrossrefMedlineGoogle Scholar - 43.
Smith KJ ,Roberts MS . Cost-effectiveness of newer treatment strategies for influenza. Am J Med. 2002;113:300-7. [PMID:12361816 ] CrossrefMedlineGoogle Scholar - 44.
Muennig PA ,Khan K . Cost-effectiveness of vaccination versus treatment of influenza in healthy adolescents and adults. Clin Infect Dis. 2001;33:1879-85. [PMID:11692300 ] CrossrefMedlineGoogle Scholar - 45.
Stange KC ,Little DW ,Blatnik B . Adverse reactions to amantadine prophylaxis of influenza in a retirement home. J Am Geriatr Soc. 1991;39:700-5. [PMID:2061537 ] CrossrefMedlineGoogle Scholar - 46.
Gravenstein S ,Davidson HE . Current strategies for management of influenza in the elderly population. Clin Infect Dis. 2002;35:729-37. [PMID:12203171 ] CrossrefMedlineGoogle Scholar
Author, Article, and Disclosure Information
From Baystate Medical Center, Springfield, Massachusetts; and Tufts University School of Medicine, Boston, Masssachusetts.
Disclosures: None disclosed.
Corresponding Author: Michael Rothberg, MD, MPH, Division of General Medicine and Geriatrics, Baystate Medical Center, 759 Chestnut Street, Springfield, MA 01199; e-mail, Michael.
Current Author Addresses: Drs. Rothberg, Bellantonio, and Rose: Division of General Medicine and Geriatrics, Baystate Medical Center, 759 Chestnut Street, Springfield, MA 01199.
Author Contributions: Conception and design: M.B. Rothberg, D.N. Rose.
Analysis and interpretation of the data: M.B. Rothberg, D.N. Rose.
Drafting of the article: M.B. Rothberg, S. Bellantonio, D.N. Rose.
Critical revision of the article for important intellectual content: M.B. Rothberg, S. Bellantonio, D.N. Rose.
Final approval of the article: M.B. Rothberg, S. Bellantonio, D.N. Rose.
Statistical expertise: M.B. Rothberg, D.N. Rose.
Administrative, technical, or logistic support: D.N. Rose.
Collection and assembly of data: M.B. Rothberg.
Submit a Comment
Contributors must reveal any conflict of interest. Comments are moderated. Please see our information for authorsregarding comments on an Annals publication.
*All comments submitted after October 1, 2021 and selected for publication will be published online only.